Oncotelic Therapeutics Completes $12.5M Asset Transfer for Nose-to-Brain Drug Delivery Platform

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has completed a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system intellectual property within the fields of biodefense and Alzheimer’s disease. In exchange, Oncotelic received $12.5 million in Series B convertible preferred stock, according to a press release issued by the company.

The N2B platform enables intranasal delivery of therapeutics directly to the central nervous system, bypassing the blood-brain barrier to allow rapid action and targeted neurological engagement. This technology has potential applications in biodefense medical countermeasures and neurodegenerative conditions, areas that Lunai Bioworks will now develop under the agreement. Oncotelic retains rights to the platform for other indications, including Parkinson’s disease and sexual dysfunction, leveraging its internal expertise in CNS therapeutics and biodefense.

The transaction supports Oncotelic’s strategy to monetize its portfolio while retaining control of core assets. The company is a clinical-stage biopharmaceutical firm focused on oncology and immunotherapy, addressing high-unmet-need cancers and rare pediatric indications. Oncotelic also benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens Oncotelic’s position in oncology and rare disease therapeutics.

This asset transfer marks a significant step in advancing CNS-targeted therapeutics, particularly for Alzheimer’s disease and biodefense applications, while providing Oncotelic with financial resources and a focused development partner. The full press release is available at https://ibn.fm/IWUpe.

For more information about Oncotelic, visit its newsroom at https://ibn.fm/OTLC.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Completes $12.5M Asset Transfer for Nose-to-Brain Drug Delivery Platform.

The post Oncotelic Therapeutics Completes $12.5M Asset Transfer for Nose-to-Brain Drug Delivery Platform appeared first on citybuzz.